UnknownNot Applicable

Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)

Spain45 participantsStarted 2020-03-12

Plain-language summary

1. Premenopausal BRCA1 / 2 or PALB2 gene mutation carriers who receive hormone replacement therapy (HRT) after preventive salpingo-oophorectomy (PBSO) have a better quality of sexual, psychological, cardiovascular and bone health than carriers who decline HRT. 2. Premenopausal mutation carriers treated with PBSO who choose HRT have a comparable overall survival and specific survival for breast / gynecological cancer to women who undergo surgery and refuse to receive HRT. 3. Premenopausal mutation carriers treated with PBSO have better overall and specific breast / gynecological cancer survival than non-SOBP carriers.

Who can participate

Age range30 Years – 49 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age between 30 and 49 years
✓. Being a member of a family with a history of hereditary breast and ovarian cancer, with a cancer risk\> 10% or being a carrier of the BRCA1 / 2 or PALB2 mutation.

Exclusion criteria

✕. Personal history of oophorectomy for benign or malignant ovarian pathology.
✕. Personal history of breast cancer.

What they're measuring

To compare the scale MenCav of quality of life in premenopausal carriers opting and rejecting hormone replacement therapy post salpingo-oophorectomy

Timeframe: 5 years

Trial details

NCT IDNCT05409222

SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-10

Contact for this trial

Teresa Ramon y Cajal, MD PhD

+ 34 93 556 56 38 tramon@santpau.cat

View on ClinicalTrials.gov More Hereditary Breast and Ovarian Cancer trials